11/18/2013 8:27:42 AM
A Cambridge company developing new drugs focused around DNA damage and genetically defined cancers has attracted investment from another pharma giant, Pfizer, in its latest funding round, a £20 million Series B. Pfizer Venture Investments was the only new investor in Mission Therapeutics’ Series B round, which was led by existing investor Sofinnova Partners and also included Imperial Innovations, SR One and Roche Venture Fund, which means it now has three major pharmaceutical companies backing it – SR One is GlaxoSmithKline’s corporate healthcare VC fund. Based at Babraham Research Campus, Mission is a Cambridge University spin-out established by the same team that set up Kudos Pharmaceuticals, which was eventually acquired by AstraZeneca for $210m in 2006.
Help employers find you! Check out all the jobs and post your resume.
comments powered by